Tremelimumab was shown not only able to suppress Treg activity, but also to replenish the effector and memory CD4+ and CD8+ T-cell numbers, contributing to its anti-tumour effect (Menard et al, 2008). This evidence concerns the gene CD4 and neoplasm.